2 results
Approved WMOCompleted
In this study, the main clinical hypothesis is that the TIMI clinically significant bleeding rates will not be different between the rivaroxaban and VKA treatment strategy groups at Month 12.
Approved WMORecruiting
To evaluate the immediate impact of TAVI or TMVr on a battery of coronary (non-) hyperemic physiology tests in patient with severe aortic valve stenosis or functional/degenerative mitral regurgitation and at least intermediate coronary artery…